PFIZER INC. DL-_05
Commented by Armin Schulz on May 7th, 2024 | 07:00 CEST
Novo Nordisk, Cardiol Therapeutics, Pfizer - Pharma Watchlist: Three top innovators
In the rapidly evolving world of biotechnology and the pharmaceutical industry, a single drug can make all the difference, especially when these drugs are unique. They have the potential to change the entire sector by setting new standards in therapy, addressing unmet medical needs, and ultimately improving the quality of life of countless patients worldwide. These drugs are often called blockbusters and generate revenue of more than USD 1 billion. Innovation often also means creating a moat against the competition. Today, we take a look at three companies that are pursuing unique approaches.
Read
Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST
Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.
Read
Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET
MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode
The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?
Read
Commented by Armin Schulz on January 3rd, 2024 | 07:10 CET
Bayer, Defence Therapeutics, Pfizer - Buckle up for the rebound
As the end of the year approaches, the savvy equity investor begins to optimize their equity portfolio for tax purposes. During this time, investors are particularly keen to review their investments and make strategic adjustments to minimize the tax burden. This approach, often referred to as "tax-loss harvesting" or "loss offsetting", involves the clever realization of losses in order to reduce capital gains tax due on profits made in the same year. This means that shares that have not performed so well over the course of the year are often sold off again in December. In the new year, the selling pressure disappears, and the shares can start their rebound. Today, we are looking at three potential candidates.
Read
Commented by André Will-Laudien on January 2nd, 2024 | 07:10 CET
Returns beckon here: The Biotech favorites for 2024! BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys in focus
The past year was a disaster for investors in the Biotech sector - no golden check as often seen before. Despite all the gloom, the key indicator, the Nasdaq Biotechnology Index (NBI), has managed an annual gain of around 7% since the end of October, thanks to a fabulous 15% upswing. The index was temporarily down 12%. High capital costs made it difficult for research-based companies to refinance, and it is only now, with falling inflation rates, that interest rate hopes are reviving. The 10-year yield in the US fell by more than 100 basis points from 4.98% to 3.84% in a short space of time. Now, the industry senses a positive outlook again. At the end of the year, the positive environment helped some Biotech stocks shake off the negative trend and initiate a turnaround. Which stocks should we focus on?
Read
Commented by Stefan Feulner on December 28th, 2023 | 07:05 CET
Liquidia, Cardiol Therapeutics, Bristol-Myers Squibb, Pfizer - Analysts comment on their favorites
The NASDAQ Biotechnology Index has been in the green since the beginning of the year with a mini gain of 1%, but the rebound since the lows at the end of October gives hope for a much more positive stock market year 2024 for the capital-intensive sector. In addition to the multiple interest rate hikes by the central banks, the biotech sector has been weighed down, in particular, by slower progress in research and development. With the expected start of a cycle of interest rate cuts, financing and capital costs are falling, which could lead to rising prices.
Read
Commented by Fabian Lorenz on December 20th, 2023 | 07:15 CET
Shares for 2024: TUI in travel boom, Pfizer with monster dividend, Almonty Industries receives millions from Germany
Three shares from three different sectors and countries: TUI, Pfizer, and Almonty Industries. Are they among the top performers in 2024? At least there are good reasons for a turnaround in all of them. At TUI, the turnaround seems to have already begun. Will it continue? Almonty Industries is facing a decisive year. With the help of Germany's KfW, a massive tungsten mine in South Korea is set to go into operation in 2024. If this succeeds, turnover and profits will likely multiply in the coming years. Like so many Corona winners, Pfizer shares have suffered withdrawal symptoms this year. Will the pharmaceutical giant get back on track in 2024 after hitting a ten-year low? In any case, the dividend yield of 6% is attractive.
Read
Commented by André Will-Laudien on November 7th, 2023 | 07:00 CET
Caution: New Corona wave ahead? BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys on the performance test bench
Smouldering lawsuits from vaccinated patients experiencing severe side effects have caused investors to doubt BioNTech and Pfizer in recent months. Will the plaintiffs be successful in court? This is rather unlikely, as the vaccine manufacturers can always invoke the time component in the fight against the pandemic. After all, what the WHO and all governments wanted was delivered: A quick solution! Moreover, these vaccines were finally approved by well-known health institutes. The biotech investment segment will become exciting again as winter approaches. The infection figures with the new coronavirus variants are rising noticeably again, and around 15% of the population wishes to get vaccinated. Where are the opportunities for investors?
Read
Commented by André Will-Laudien on October 26th, 2023 | 08:15 CEST
Omicron or Pirola? Biotech shows doubling opportunities again! BioNTech, Pfizer, Defence Therapeutics, MorphoSys in focus
We had ticked off the Corona pandemic long ago. But if you ask your acquaintances, you may find one or two who have recently been infected with the "Pirola" variant. The official code of the virus variant is BA.2.86, and it was first discovered in Israel. The current infections are spreading rapidly across Europe and have also reached Germany. So far, the new Omicron offshoot appears less contagious than its predecessors. The new symptoms associated with "Pirola" include skin rashes, diarrhea, changes in the mouth and tongue, itchy eyes and surprisingly, sore fingers or toes. What is going on here? It is a reason to look again at BioNTech and some other biotechs. Where are the opportunities lurking?
Read
Commented by Nico Popp on September 13th, 2023 | 08:30 CEST
Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer
Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.
Read